Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Nov 22;13:1092147. doi: 10.3389/fphar.2022.1092147

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Frontiers Production Office 1,*
PMCID: PMC9724764  PMID: 36483732

Due to a mistake on the publisher’s part, this article was originally published as a Systematic Review instead of Original Research.

The publisher apologizes for this error and states that this does not change the scientific conclusions of the article in any way. The original article has been updated.


Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES